| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal. The Google-owned fitness tracker maker is teaming up with Quest Diagnostics, according to a Wednesday release, to study how the combination of the two companies’ products could potentially help improve metabolic health, which is linked to conditions like diabetes, heart disease and stroke.
Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas. In addition, subject to transfer of the laboratory license, Quest has also acquired certain assets from the laboratory business serving Hawthorn Medical Associates in Dartmouth, MA.
Haystack Oncology said on Monday that it has struck a deal to investigate the use of its minimal residual disease (MRD) testing technology in non-small cell lung cancer (NSCLC) in collaboration with research organization Alliance Foundation Trials (AFT).
Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.
Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.